Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review

Marat Fudim, William T. Abraham, Ralph Stephan von Bardeleben, Jo Ann Lindenfeld, Piotr P. Ponikowski, Husam M. Salah, Muhammad Shahzeb Khan, Horst Sievert, Gregg W. Stone, Stefan D. Anker, Javed Butler

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


The regulatory landscape for device-based heart failure (HF) therapies has seen a major shift in the last 7 years. In 2013, the U.S. Food and Drug Administration released guidance for early feasibility and first-in-human studies, thereby encouraging device innovation, and in 2016 the U.S. Congress authorized the Breakthrough Devices Program to expedite access for Americans to innovative devices indicated for diagnosis and treatment of serious illnesses, such as HF. Since December 2016, there has been an increase in the number of HF devices for which manufacturers are seeking approval through the breakthrough designation pathway. This has led to a rapid uptake in the development and evaluation of device-based HF therapies. This article reviews the current and future landscape of device therapies for chronic HF and associated comorbidities and the regulatory environment that is driving current and future innovation.

Original languageEnglish
Pages (from-to)931-956
Number of pages26
JournalJournal of the American College of Cardiology
Issue number9
StatePublished - 31 Aug 2021


  • U.S. Food and Drug Administration
  • device therapy
  • heart failure


Dive into the research topics of 'Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review'. Together they form a unique fingerprint.

Cite this